Cd34+ bone marrow stem cells intravitreal (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
90 | 網膜色素変性症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01736059 (ClinicalTrials.gov) | July 2012 | 25/7/2012 | Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy | A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy | Non-exudative Age-related Macular Degeneration;Diabetic Retinopathy;Retina Vein Occlusion;Retinitis Pigmentosa;Hereditary Macular Degeneration | Drug: CD34+ bone marrow stem cells intravitreal | University of California, Davis | NULL | Enrolling by invitation | 18 Years | 100 Years | All | 15 | Phase 1 | United States |